Antibiotic Collaboration and Licensing Deals 2016-2025
상품코드:1881256
리서치사:Current Partnering
발행일:2025년 11월
페이지 정보:영문 100+ Pages
라이선스 & 가격 (부가세 별도)
한글목차
이 보고서는 세계 바이오의약품 산업에 대해 조사 분석했으며, 2016-2025년 항생제 공동연구 및 라이선싱 계약 137건에 대한 상세한 데이터를 제공합니다.
목차
개요
제1장 서론
제2장 항생제 계약의 동향
서론
과거 수년간 항생제 계약
가장 활발한 항생제 계약 기업
항생제 계약 : 계약 유형별
항생제 계약 : 치료 영역별
항생제 계약 : 산업 부문별
항생제 계약 계약 조건
항생제 계약 헤드라인 금액
항생제 계약 선불
항생제 계약 마일스톤 지불
항생제 로열티율
제3장 주요 항생제 계약
서론
금액별 상위 항생제 계약
제4장 가장 활발한 항생제 계약 기업
서론
가장 활발한 항생제 계약 기업
가장 활발한 항생제 계약 기업 개요
제5장 항생제 계약 디렉토리
서론
항생제 계약 디렉토리
제6장 항생제 계약 : 기술 유형별
계약 디렉토리
계약 디렉토리 - 항생제 계약 : 기업별(A-Z)
계약 디렉토리 - 항생제 계약 : 계약 유형별
계약 디렉토리 - 항생제 계약 : 치료 영역별
계약 유형 정의
Biopharma Research Ltd 소개
Current Partnering
Current Agreements
Current Partnering의 최근 리포트 타이틀
KSA
영문 목차
영문목차
Antibiotic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the antibiotic deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of antibiotic deals from 2016 to 2025.
The report provides a detailed understanding and analysis of how and why companies enter antibiotic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 137 antibiotic deals announced since 2016 including financial terms where available including links to online deal records of actual antibiotic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of antibiotic dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in antibiotic dealmaking since 2016.
Chapter 3 provides an overview of the leading antibiotic deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in antibiotic dealmaking with a brief summary followed by a comprehensive listing of antibiotic deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of antibiotic deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of antibiotic partnering deals signed and announced since Jan 2016. The chapter is organized by specific antibiotic technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in antibiotic deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key benefits
Antibiotic Collaboration and Licensing Deals provides the reader with the following key benefits:
Understand deal trends since 2016
Browse antibiotic collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time
Report scope
Antibiotic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of antibiotic trends and structure of deals entered into by leading biopharma companies worldwide.
Antibiotic Collaboration and Licensing Deals includes:
Trends in antibiotic dealmaking in the biopharma industry
Directory of antibiotic deal records covering pharmaceutical and biotechnology
The leading antibiotic deals by value
Most active antibiotic licensing dealmakers
Antibiotic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in antibiotic dealmaking
2.1. Introduction
2.2. Antibiotic deals over the years
2.3. Most active antibiotic dealmakers
2.4. Antibiotic deals by deal type
2.5. Antibiotic deals by therapy area
2.6. Antibiotic deals by industry sector
2.7. Deal terms for antibiotic deals
2.7.1 Antibiotic deals headline values
2.7.2 Antibiotic deal upfront payments
2.7.3 Antibiotic deal milestone payments
2.7.4 Antibiotic royalty rates
Chapter 3 - Leading antibiotic deals
3.1. Introduction
3.2. Top antibiotic deals by value
Chapter 4 - Most active antibiotic dealmakers
4.1. Introduction
4.2. Most active antibiotic dealmakers
4.3. Most active antibiotic deals company profiles
